The world’s largest COVID-19 vaccine test began on Monday and the first of 30,000 volunteers is expected to review vaccines created through the U.S. government, one of many applicants in the final stretch of the global vaccine race.
There is still no guarantee that the experimental vaccine, developed through the National Institutes of Health and Modern Inc., will protect.
Mandatory testing: Volunteers won’t know if they get the genuine photo or a fake version. After two doses, scientists will largely monitor which organization reports the maximum number of infections in its daily activities, especially in areas where the virus is still spreading unchecked.
“Unfortunately for the United States of America, we have plenty of infections right now” to get that answer, NIH’s Dr. Anthony Fauci recently told The Associated Press.
Modern said vaccination took place in Savannah, Georgia, the first site to begin among more than seven dozen checkpoints across the country.
Several other vaccines manufactured through China and the British University of Oxford earlier this month began smaller final phase tests in Brazil and other heavily affected countries.
But the U.S. They are not easy to test for any vaccine that can be used in the country and have set the bar very high: month to autumn, the government-funded COVID-19 prevention network will launch a new test on a leading candidate – one with 30,000 newly recruited volunteers.
Mass studies not only try to check if vaccines are working, but are necessary to verify the protection of each and every possible vaccine. And following the same review regulations will allow scientists to eventually compare all plans.
Then, in August, the final examination of the shooting begins at Oxford, followed by plans to check a Johnson and Johnson candidate in September and Novavax in October, if everything goes according to plan. Pfizer Inc. is making plans for its own study of 30,000 people this summer.
That’s an impressive number of other people who had to roll up their ass for science. But in recent weeks, more than 150,000 Americans have filed an online record indicating their interest, said Dr. Larry Corey, virologist at the Fred Hutchinson Cancer Research Institute in Seattle, who is helping oversee test sites.
“These trials will have to be multigenerational, they will have to be multiethnic, they will have to reflect the diversity of the American population,” Corey said at a vaccine assembly last week. He stated that it was vital to ensure a sufficient number of black and Hispanic participants, as these populations are greatly affected by COVID-19.
It takes years to create a new vaccine from scratch, but this time scientists are setting speed records, encouraged by the wisdom that vaccination is the world’s most productive hope opposed to the pandemic. Coronavirus was not even known until last December, and vaccine brands came into action on January 10 when China shared the genetic series of the virus.
Only 65 days later, in March, the vaccine manufactured by NIH was tested in humans. The first recipient encourages others to volunteer now.
“We all feel so powerless right now. There’s not much we can do to fight this virus. And participating in this rehearsal made me feel like I was doing something,” Jennifer Haller of Seattle told ap. “Get ready for a lot of questions from your friends and the family circle about how it’s going, and thank you very much.”
That first-stage study that included Haller and 44 others showed the shots revved up volunteers’ immune systems in ways scientists expect will be protective, with some minor side effects such as a brief fever, chills and pain at the injection site. Early testing of other leading candidates have had similarly encouraging results.
If everything goes right with the final studies, it still will take months for the first data to trickle in from the Moderna test, followed by the Oxford one.
Governments around the world are looking to buy millions of doses of these lead candidates, so if regulators approve one or more vaccines, vaccines can start right away. But the first doses obtained will be rationed, possibly reserved for those most threatened by the virus.
“We are optimistic, cautiously optimistic” that the vaccine will work and that “by the end of the year” there will be knowledge to produce it, Dr. Stephen Hoge, president of Moderna, founded in Massachusetts, told a subcommittee in the House of Representatives. Week.
Until then, Haller, the volunteer vaccinated in March, wears a mask in public and takes the same precautions away with everyone, in the hope that one of the vaccines will be carried out in the pipeline.
“I don’t know what the chances are that this is precisely the right vaccine. But thank God there are so many others fighting this right now,” he said.
___
AP photographer Ted Warren in Seattle contributed to this report.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.